Cornerstone Advisors LLC Raises Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cornerstone Advisors LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 31.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,900 shares of the biopharmaceutical company's stock after purchasing an additional 1,900 shares during the quarter. Cornerstone Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $5,627,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Amundi raised its holdings in shares of Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock valued at $1,138,074,000 after purchasing an additional 487,489 shares in the last quarter. Proficio Capital Partners LLC lifted its position in shares of Regeneron Pharmaceuticals by 92,865.3% during the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock valued at $156,284,000 after buying an additional 219,162 shares in the last quarter. Worldquant Millennium Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $127,489,000. KBC Group NV grew its position in shares of Regeneron Pharmaceuticals by 296.7% in the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company's stock valued at $97,338,000 after purchasing an additional 102,198 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $65,180,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of equities analysts recently weighed in on REGN shares. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective for the company. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, December 17th. Bank of America reaffirmed an "underperform" rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Finally, UBS Group lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $973.13.

Regeneron Pharmaceuticals Trading Down 3.5 %

Shares of NASDAQ:REGN traded down $25.26 during trading on Wednesday, reaching $692.91. The company's stock had a trading volume of 540,649 shares, compared to its average volume of 619,969. The stock has a market capitalization of $75.75 billion, a PE ratio of 18.08, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The firm's 50 day simple moving average is $697.08 and its two-hundred day simple moving average is $842.19. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the firm posted $11.86 EPS. Regeneron Pharmaceuticals's revenue for the quarter was up 10.3% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.51%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.